Business Wire

CO-PROMETHEUS-MATERIALS

12.1.2023 14:01:40 CET | Business Wire | Press release

Share
Prometheus Materials Appoints Vishaan Chakrabarti to Board of Directors

Prometheus Materials, a leader in sustainable building materials, today announced the appointment of Vishaan Chakrabarti, FAIA FRAIC, to its Board of Directors. Chakrabarti joins a dedicated leadership team working to harness Prometheus Materials’ technology to accelerate the world’s transition to a carbon-negative future.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230112005190/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Vishaan Chakrabarti, FAIA FRAIC – Founder and Creative Director of Practice for Architecture and Urbanism (PAU) – joins the Prometheus Materials Board of Directors. (Photo: Business Wire)

This Board addition comes on the heels of multiple company milestones. In June 2022, Prometheus Materials announced its $8 Million Series A Funding Round led by Paris-based VC firm Sofinnova Partners, with participation by the Microsoft Climate Innovation Fund, Skidmore, Owings & Merrill (SOM), GAF, and The Autodesk Foundation. In July 2022, Prometheus Materials and SOM announced a partnership to ultimately develop zero-carbon building materials.

“We are thrilled to welcome Vishaan to our board,” said Loren Burnett, President and CEO of Prometheus Materials. “Vishaan has unique expertise to help guide the company through new levels of growth – conducting key advocacy work in the market at-large to promote sustainable legislation, helping to drive critical industry connections, and addressing market awareness and acceptance around the benefits of sustainable building materials.”

Chakrabarti brings a wealth of experience to his new role, in which he has acutely focused on sustainable design. He is the Founder and Creative Director of Practice for Architecture & Urbanism (PAU), a design firm dedicated to lasting architecture and human urbanism to advance healthy cities. Previously, he served as Director of Planning for Manhattan, assisting in the reconstruction of the new World Trade Center and the design of New York City’s High Line and 7 Line expansion, among other projects. He also served as Dean at the University of California - Berkeley College of Environmental Design, and has given main stage TED Talks on sustainability in architecture and urban design.

“Joining Prometheus Materials’ board feels like a natural extension of the mission of my life’s work,” said Chakrabarti. “There will be an avalanche of growth in the demand for sustainable building materials in the coming years and Prometheus Materials’ technology is vital in addressing a key polluting sector. Concrete is one of the world’s primary building materials and I’m honored to work with this team to help change the status quo of urban design through sustainable materials.”

Cement production accounts for 8% of annual CO2 emissions and consumes 9% of annual industrial water production on a global basis. In contrast to traditional portland-based cement, the production of Prometheus Materials' microalgae-based building materials emits little-to-no CO2 and recycles 95% of the water used.

About Prometheus Materials

Prometheus Materials provides sustainable building materials that accelerate the world’s transition to a carbon-negative future. Inspired by biological processes found in nature, the company's process uses microalgae to produce a bio-cement that offers an alternative to carbon-intensive portland cement. When mixed with aggregate, this bio-cement forms an ultra low-carbon bio-concrete with mechanical, physical, and thermal properties that rival those of portland cement-based concrete. Learn more about how the company enables the decarbonization of the construction industry at prometheusmaterials.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230112005190/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Duco Launches the First Agentic Operations Platform for Financial Services27.5.2026 09:20:00 CEST | Press release

Duco, today launched the first agentic Operations platform for financial services. Built on the engine that already processes 20 billion transactions every month for more than 200 clients, including seven of the top 20 banks and ten of the top 20 asset managers, the platform brings together everything firms need to run post-trade Operations alongside autonomous agents, safely and at scale. The launch establishes a breakthrough the industry has been waiting for. A tool surface, purpose-built for agents. Duco has unbundled its platform into a new alternative agent layer that reconfigures its platform into hundreds of discrete capabilities servicing post trade. Model Context Protocol (MCP) gives capabilities covering reconciliation, data preparation, data access, audit trails, exception management, document creation and more. For the first time, agents have a verified, deterministic toolset built specifically for post-trade. Agents do not replace matching, rules or audit; they use them. P

Brenus Pharma Announces FDA Acceptance of IND Application for STC-1010 (BreAK-CRC001) in MSS Metastatic Colorectal Cancer (mCRC)27.5.2026 08:49:00 CEST | Press release

STC-1010 is a first-in-class allogeneic in vivo immunotherapy for which the FDA has authorized clinical evaluation in the U.S. under the BreAK-CRC001 study. This strategic milestone enables the company to execute a global clinical strategy following European regulatory approvals (ANSM, AFMPS), first patients dosed with preliminary results and good tolerability observed in early Phase Ia. First data are expected to be presented during ESMO annual congress 2026. Brenus Pharma, a clinical stage biotechnology company developing novel in vivo immunotherapies for solid tumors, announced that the U.S. Food and Drug Administration (FDA) has accept the company's Investigational New Drug (IND) application for its first drug candidate, STC-1010, in microsatellite stable (MSS) metastatic colorectal cancer (mCRC). STC-1010 is designed to address a critical unmet need worldwide. Approximately 95% of mCRC patients have MSS tumors, which demonstrate minimal response to standard immunotherapies. The FD

Tide Crosses 2 Million Members Worldwide - Big Step Forward in Mission to Support and Grow Small Businesses27.5.2026 08:00:00 CEST | Press release

Continuing to grow in the UK and internationally, with India seeing especially strong member growth in the last 12 months In the UK, Tide has 15% market share and has helped small businesses access over £1.75bn in credit Rapid roll out of products; from admin, accounting and tax tools; subscription options; payment solutions; government registrations; bill payments and credit Tide, the UK’s leading business management platform, today announces it has crossed 2 million members globally, with India in particular seeing strong growth. More than 1.1 million small businesses joined Tide in India since the company launched there in December 2022. This makes India Tide’s fastest-growing market by member acquisition. The UK is Tide’s home market, with 900,000 SMEs, 15% market share, and the majority of the company’s revenue. Tide’s steadily expanding its presence in Europe, with Germany and France, where the platform is gaining strong traction, thanks to millions of small businesses turning to

Alfasigma presents first data on filgotinib from the Phase 3 OLINGUITO trial in axial spondyloarthritis at EULAR 202627.5.2026 08:00:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific and investor media only.In the OLINGUITO Phase 3 study in radiographic (r) and non-radiographic (nr) axial spondyloarthritis (axSpA) a significantly greater proportion of patients achieved the prespecified primary endpoint of ASAS40 with filgotinib compared with placebo at week 16.The improvements in signs and symptoms of axSpA with filgotinib, an oral, once-daily JAK1 preferential inhibitor, were observed as early as week 1 and maintained over 52 weeks of treatment.In the r-axSpA and nr-axSpA filgotinib groups, of those achieving a response in the prespecified primary endpoint of ASAS40 at week 16, 84.6% and 78.0% maintained their responses to week 52, respectively.In OLINGUITO no new safety signals were observedfor filgotinib over 52 weeks, and the safety profile was consistent with the known overall safety profile.Primary results from the Phase 3 OLINGUITO tria

Royal London Asset Management Expands Relationship with SS&C to Service New Australian Funds27.5.2026 00:00:00 CEST | Press release

SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced that Royal London Asset Management, a leading U.K. fund management company, has extended its relationship with SS&C. SS&C Global Investor & Distribution Solutions will provide fund administration and unit registry services for its new range of Australian active funds, including: Royal London Global Equity Diversified Fund Royal London Global Equity Enhanced Fund Royal London Global Equity Select Fund Royal London Short Duration Global High Yield Bond Fund RLAM is part of Royal London, the U.K.’s largest mutual life, pensions and investment company. SS&C services approximately £72bn in assets under management across its U.K. fund range. Equity Trustees will serve as the Responsible Entity for RLAM’s new funds, which have launched with around AUD $1 billion in AUM. The unit trusts are structured as feeder funds, providing investors with indirect exposure to RLAM’s range of Dublin-domiciled Undertakings for Collective Investm

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye